Synergistic metabolic benefits of an exenatide analogue and cholecystokinin in diet-induced obese and leptin-deficient rodents

Diabetes, Obesity and Metabolism

Volumn 17, Issue 1, 2015, Pages 61-73

  Trevaskis, J L ^a,b   Sun, C ^a   Athanacio, J ^a   D'Souza, L ^a   Samant, M ^a   Tatarkiewicz, K ^a   Griffin, P S ^a   Wittmer, C ^a   Wang, Y ^a   Teng, C H ^a   Forood, B ^a   Parkes, D G ^a   Roth, J D ^a  

^a AMYLIN PHARMACEUTICALS INC   (United States)

^b MEDIMMUNE   (United States)

Author keywords

Antidiabetic drug; Experimental pharmacology; GLP 1 analogue; Weight loss therapy

Indexed keywords

AC 170236; AC 3174; AMYLIN; ANTIDIABETIC AGENT; ANTIOBESITY AGENT; CHOLECYSTOKININ A RECEPTOR; CHOLECYSTOKININ B RECEPTOR; CHOLECYSTOKININ OCTAPEPTIDE; CHOLECYSTOKININ RECEPTOR STIMULATING AGENT; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; GLYCOSYLATED HEMOGLOBIN; KAOLIN; LEPTIN; UNCLASSIFIED DRUG; AC3174; CHOLECYSTOKININ; GLP1R PROTEIN, MOUSE; GLP1R PROTEIN, RAT; GLUCAGON RECEPTOR; PEPTIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DIET INDUCED OBESITY; DRUG POTENTIATION; DRUG RECEPTOR BINDING; ENERGY EXPENDITURE; FOOD INTAKE; LEPTIN DEFICIENCY; LIPID DIET; MALE; METABOLISM; MONOTHERAPY; NAUSEA; NONHUMAN; PICA; PROTEIN ACETYLATION; RAT; RESPONSE SURFACE METHOD; TREATMENT DURATION; WEIGHT REDUCTION; ACETYLATION; ADVERSE EFFECTS; AGONISTS; ANALOGS AND DERIVATIVES; ANIMAL; CALORIC INTAKE; COMPARATIVE STUDY; COMPLICATION; DIABETES MELLITUS; DRUG COMBINATION; DRUG EFFECTS; MUTANT MOUSE STRAIN; OBESITY; RANDOMIZATION; SPRAGUE DAWLEY RAT; SUBCUTANEOUS DRUG ADMINISTRATION;

ACETYLATION; ANIMALS; ANTI-OBESITY AGENTS; CHOLECYSTOKININ; DIABETES MELLITUS; DIET, HIGH-FAT; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; ENERGY INTAKE; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; HYPOGLYCEMIC AGENTS; INFUSIONS, SUBCUTANEOUS; ISLET AMYLOID POLYPEPTIDE; MALE; MICE, MUTANT STRAINS; OBESITY; PEPTIDES; RANDOM ALLOCATION; RATS, SPRAGUE-DAWLEY; RECEPTOR, CHOLECYSTOKININ A; RECEPTOR, CHOLECYSTOKININ B; RECEPTORS, GLUCAGON; WEIGHT LOSS;

EID: 84919497072     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12390     Document Type: Article

References (60)

1. Mack C, Wilson J, Athanacio J et al. Pharmacological actions of the peptide hormone amylin in the long-term regulation of food intake, food preference, and body weight. Am J Physiol Regul Integr Comp Physiol 2007; 293: R1855-R1863.
2. Hayes MR, Kanoski SE, Alhadeff AL, Grill HJ. Comparative effects of the long-acting GLP-1 receptor ligands, liraglutide and exendin-4, on food intake and body weight suppression in rats. Obesity (Silver Spring) 2011; 19: 1342-1349.
3. West DB, Fey D, Woods SC. Cholecystokinin persistently suppresses meal size but not food intake in free-feeding rats. Am J Physiol 1984; 246(5 Pt 2): R776-R787.
4. Crawley JN, Beinfeld MC. Rapid development of tolerance to the behavioural actions of cholecystokinin. Nature 1983; 302: 703-706.
5. Folli F, Guardado Mendoza R. Potential use of exenatide for the treatment of obesity. Expert Opin Investig Drugs 2011; 20: 1717-1722.
6. Smith SR, Aronne LJ, Burns CM, Kesty NC, Halseth AE, Weyer C. Sustained weight loss following 12-month pramlintide treatment as an adjunct to lifestyle intervention in obesity. Diabetes Care 2008; 31: 1816-1823.
7. Kissileff HR, Pi-Sunyer FX, Thornton J, Smith GP. C-terminal octapeptide of cholecystokinin decreases food intake in man. Am J Clin Nutr 1981; 34: 154-160.
8. Geary N, Kissileff HR, Pi-Sunyer FX, Hinton V. Individual, but not simultaneous, glucagon and cholecystokinin infusions inhibit feeding in men. Am J Physiol 1992; 262(6 Pt 2): R975-R980.
9. MacIntosh CG, Morley JE, Wishart J et al. Effect of exogenous cholecystokinin (CCK)-8 on food intake and plasma CCK, leptin, and insulin concentrations in older and young adults: evidence for increased CCK activity as a cause of the anorexia of aging. J Clin Endocrinol Metab 2001; 86: 5830-5837.
10. Jordan J, Greenway FL, Leiter LA et al. Stimulation of cholecystokinin-A receptors with GI181771X does not cause weight loss in overweight or obese patients. Clin Pharmacol Ther 2008; 83: 281-287.
11. Barrachina MD, Martinez V, Wang L, Wei JY, Tache Y. Synergistic interaction between leptin and cholecystokinin to reduce short-term food intake in lean mice. Proc Natl Acad Sci U S A 1997; 94: 10455-10460.
12. Matson CA, Reid DF, Cannon TA, Ritter RC. Cholecystokinin and leptin act synergistically to reduce body weight. Am J Physiol Regul Integr Comp Physiol 2000; 278: R882-R990.
13. Wang L, Barachina MD, Martinez V, Wei JY, Tache Y. Synergistic interaction between CCK and leptin to regulate food intake. Regul Pept 2000; 92: 79-85.
14. de Lartigue G, Barbier de la Serre C, Espero E, Lee J, Raybould HE. Leptin resistance in vagal afferent neurons inhibits cholecystokinin signaling and satiation in diet induced obese rats. PLoS ONE 2012; 7: e32967.
15. Trevaskis JL, Turek VF, Griffin PS, Wittmer C, Parkes DG, Roth JD. Multi-hormonal weight loss combinations in diet-induced obese rats: therapeutic potential of cholecystokinin? Physiol Behav 2010; 100: 187-195.
16. Bhavsar S, Watkins J, Young A. Synergy between amylin and cholecystokinin for inhibition of food intake in mice. Physiol Behav 1998; 64: 557-561.
17. Fehmann HC, Goke B, Weber V et al. Interaction of glucagon-like peptide-1 (7-36)amide and cholecystokinin-8 in the endocrine and exocrine rat pancreas. Pancreas 1990; 5: 361-365.
18. Brennan IM, Feltrin KL, Horowitz M et al. Evaluation of interactions between CCK and GLP-1 in their effects on appetite, energy intake, and antropyloroduodenal motility in healthy men. Am J Physiol Regul Integr Comp Physiol 2005; 288: R1477-R1485.
19. Gutzwiller JP, Degen L, Matzinger D, Prestin S, Beglinger C. Interaction between GLP-1 and CCK-33 in inhibiting food intake and appetite in men. Am J Physiol Regul Integr Comp Physiol 2004; 287: R562-R567.
20. Hargrove DM, Kendall ES, Reynolds JM et al. Biological activity of AC3174, a peptide analog of exendin-4. Regul Pept 2007; 141: 113-119.
21. Miranda MT, Liddle RA, Rivier JE. Synthesis of human CCK26-33 and CCK-33 related analogues on 2, 4-DMBHA and TMBHA. J Med Chem 1993; 36: 1681-1688.
22. Praissman M, Fara JW, Praissman LA, Berkowitz JM. Preparation of an N-acetyl-octapeptide of cholecystokinin. The role of N-acetylation in protecting the octapeptide from degradation by smooth muscle tissues. Biochim Biophys Acta 1982; 716: 240-248.
23. Pierson ME, Comstock JM, Simmons RD, Julien R, Kaiser F, Rosamond JD. CCK peptides with combined features of hexa- and tetrapeptide CCK-A agonists. J Med Chem 2000; 43: 2350-2355.
24. Corringer PJ, Weng JH, Ducos B et al. CCK-B agonist or antagonist activities of structurally hindered and peptidase-resistant Boc-CCK4 derivatives. J Med Chem 1993; 36: 166-172.
25. Takeda N, Hasegawa S, Morita M, Matsunaga T. Pica in rats is analogous to emesis: an animal model in emesis research. Pharmacol Biochem Behav 1993; 45: 817-821.
26. Wang Y, Roth JD, Taylor SW. Simultaneous quantification of the glucagon-like peptide-1 (GLP-1) and cholecystokinin (CCK) receptor agonists in rodent plasma by on-line solid phase extraction and LC-MS/MS. J Chromatogr B Analyt Technol Biomed Life Sci 2014; 957: 24-29.
27. Khuri AI, Mukhopadhyay S. Response surface methodology. Wiley Interdiscip Rev Comput Stat 2010; 2: 128-149.
28. Lampel M, Kern HF. Acute interstitial pancreatitis in the rat induced by excessive doses of a pancreatic secretagogue. Virchows Arch A Pathol Anat Histol 1977; 373: 97-117.
29. Mack CM, Moore CX, Jodka CM et al. Antiobesity action of peripheral exenatide (exendin-4) in rodents: effects on food intake, body weight, metabolic status and side-effect measures. Int J Obes (Lond) 2006; 30: 1332-1340.
30. Dufresne M, Seva C, Fourmy D. Cholecystokinin and gastrin receptors. Physiol Rev 2006; 86: 805-847.
31. Raybould HE, Gayton RJ, Dockray GJ. Mechanisms of action of peripherally administered cholecystokinin octapeptide on brain stem neurons in the rat. J Neurosci 1988; 8: 3018-3024.
32. Wang H, Wong PT, Spiess J, Zhu YZ. Cholecystokinin-2 (CCK2) receptor-mediated anxiety-like behaviors in rats. Neurosci Biobehav Rev 2005; 29: 1361-1373.
33. Lavine JA, Raess PW, Stapleton DS et al. Cholecystokinin is up-regulated in obese mouse islets and expands beta-cell mass by increasing beta-cell survival. Endocrinology 2010; 151: 3577-3588.
34. Moran TH, McHugh PR. Gastric and nongastric mechanisms for satiety action of cholecystokinin. Am J Physiol 1988; 254(4 Pt 2): R628-R632.
35. Rushakoff RJ, Goldfine ID, Carter JD, Liddle RA. Physiological concentrations of cholecystokinin stimulate amino acid-induced insulin release in humans. J Clin Endocrinol Metab 1987; 65: 395-401.
36. Young AA, Gedulin BR, Rink TJ. Dose-responses for the slowing of gastric emptying in a rodent model by glucagon-like peptide (7-36) NH2, amylin, cholecystokinin, and other possible regulators of nutrient uptake. Metabolism 1996; 45: 1-3.
37. Beglinger S, Drewe J, Schirra J, Goke B, D'Amato M, Beglinger C. Role of fat hydrolysis in regulating glucagon-like Peptide-1 secretion. J Clin Endocrinol Metab 2010; 95: 879-886.
38. Mizuno A, Kuwajima M, Ishida K et al. Extrapancreatic action of truncated glucagon-like peptide-I in Otsuka Long-Evans Tokushima Fatty rats, an animal model for non-insulin-dependent diabetes mellitus. Metabolism 1997; 46: 745-749.
39. Hayes MR, Kanoski SE, De Jonghe BC et al. The common hepatic branch of the vagus is not required to mediate the glycemic and food intake suppressive effects of glucagon-like-peptide-1. Am J Physiol Regul Integr Comp Physiol 2011; 301: R1479-R1485.
40. Smith GP, Jerome C, Cushin BJ, Eterno R, Simansky KJ. Abdominal vagotomy blocks the satiety effect of cholecystokinin in the rat. Science 1981; 213: 1036-1037.
41. Blevins JE, Eakin TJ, Murphy JA, Schwartz MW, Baskin DG. Oxytocin innervation of caudal brainstem nuclei activated by cholecystokinin. Brain Res 2003; 993: 30-41.
42. Hayes MR, Leichner TM, Zhao S et al. Intracellular signals mediating the food intake-suppressive effects of hindbrain glucagon-like peptide-1 receptor activation. Cell Metab 2011; 13: 320-330.
43. Rinaman L. Interoceptive stress activates glucagon-like peptide-1 neurons that project to the hypothalamus. Am J Physiol 1999; 277: R582-R590.
44. Fan W, Ellacott KL, Halatchev IG, Takahashi K, Yu P, Cone RD. Cholecystokinin-mediated suppression of feeding involves the brainstem melanocortin system. Nat Neurosci 2004; 7: 335-336.
45. Hisadome K, Reimann F, Gribble FM, Trapp S. CCK stimulation of GLP-1 neurons involves alpha1-adrenoceptor-mediated increase in glutamatergic synaptic inputs. Diabetes 2011; 60: 2701-2709.
46. Gier B, Matveyenko AV, Kirakossian D, Dawson D, Dry SM, Butler PC. Chronic GLP-1 receptor activation by exendin-4 induces expansion of pancreatic duct glands in rats and accelerates formation of dysplastic lesions and chronic pancreatitis in the Kras(G12D) mouse model. Diabetes 2012; 61: 1250-1262.
47. Chadwick KD, Fletcher AM, Parrula MC et al. Occurrence of spontaneous pancreatic lesions in normal and diabetic rats: a potential confounding factor in the nonclinical assessment of GLP-1-based therapies. Diabetes 2014; 63: 1303-1314.
48. Roy D, Chadwick KD, Tatarkiewicz K et al. The glucagon-like peptide-1-based therapeutics exenatide and saxagliptin did not cause detrimental effects on the pancreas in mice, rats, dogs and monkeys. Diabetes Obes Metab 2014; 16: 910-921.
49. Tatarkiewicz K, Smith PA, Sablan EJ et al. Exenatide does not evoke pancreatitis and attenuates chemically induced pancreatitis in normal and diabetic rodents. Am J Physiol Endocrinol Metab 2010; 299: E1076-E1086.
50. Tatarkiewicz K, Belanger P, Gu G, Parkes D, Roy D. No evidence of drug-induced pancreatitis in rats treated with exenatide for 13 weeks. Diabetes Obes Metab 2013; 15: 417-426.
51. Vrang N, Jelsing J, Simonsen L et al. The effects of 13 wk of liraglutide treatment on endocrine and exocrine pancreas in male and female ZDF rats: a quantitative and qualitative analysis revealing no evidence of drug-induced pancreatitis. Am J Physiol Endocrinol Metab 2012; 303: E253-E264.
52. Jensen RT. Involvement of cholecystokinin/gastrin-related peptides and their receptors in clinical gastrointestinal disorders. Pharmacol Toxicol 2002; 91: 333-350.
53. Marino AB, Cole SW, Nuzum DS. Alternative dosing strategies for liraglutide in patients with type 2 diabetes mellitus. Am J Health Syst Pharm 2014; 71: 223-226.
54. Weintraub M, Sundaresan PR, Schuster B, Moscucci M, Stein EC. Long-term weight control study. III (weeks 104 to 156). An open-label study of dose adjustment of fenfluramine and phentermine. Clin Pharmacol Ther 1992; 51: 602-607.
55. Roth JD, Roland BL, Cole RL et al. Leptin responsiveness restored by amylin agonism in diet-induced obesity: evidence from nonclinical and clinical studies. Proc Natl Acad Sci U S A 2008; 105: 7257-7262.
56. Aronne LJ, Halseth AE, Burns CM, Miller S, Shen LZ. Enhanced weight loss following coadministration of pramlintide with sibutramine or phentermine in a multicenter trial. Obesity (Silver Spring) 2010; 18: 1739-1746.
57. Greenway FL, Whitehouse MJ, Guttadauria M et al. Rational design of a combination medication for the treatment of obesity. Obesity (Silver Spring) 2009; 17: 30-39.
58. Gadde KM, Allison DB, Ryan DH et al. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial. Lancet 2011; 377: 1341-1352.
59. Berthoud HR. Synergy: a concept in search of a definition. Endocrinology 2013; 154: 3974-3977.
60. Roth JD, Trevaskis JL, Turek VF, Parkes DG. "Weighing in" on synergy: preclinical research on neurohormonal anti-obesity combinations. Brain Res 2010; 1350: 86-94.